The event, by the filing. Vertex's annual report on Form 10-K, filed February 13, 2025, discloses that in January 2025 Journavx was approved by the FDA as a treatment for moderate-to-severe acute pain in adults. The company's proxy statement describes Journavx as a first-in-class, oral pain signal inhibitor and a non-opioid mechanism — the NaV1.8 sodium-channel pathway.
What an approval actually obligates, and what it unlocks, is the business question. Vertex's Q2 2025 quarterly disclosure framed Journavx as the company's selective non-opioid NaV1.8 pain signal inhibitor, approved for people with acute pain, and noted the drug became available at pharmacies in March 2025 — meaning the commercial clock started mid-quarter, not at approval.
The uptake choreography is visible across consecutive 10-Qs. By the company's Q3 2025 reporting the filing described patient volumes since launch, and the Q1 2026 10-Q, filed May 5, 2026, points to an accelerated review timeline for a follow-on submission once accepted — the disclosure language of a franchise the company is trying to broaden beyond acute pain into neuropathic indications.
The stakes-aware read: this is a launch into one of the most heavily prescribed therapeutic categories in medicine, with a differentiated non-opioid mechanism. But topline launch color in a 10-Q is not the same as a mature revenue line — the filings describe early adoption and expanded-indication ambition, not a settled commercial outcome.
The endpoint and launch language above is quoted from Vertex's primary SEC filings, surfaced via EdgarBeast as a filing-evidence index — the Q1 2026 10-Q and the FY2024 10-K on sec.gov.